Burkholderia Pseudomallei Infections (Melioidosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Burkholderia pseudomallei are a gram negative, bipolar, aerobic, motile rod-shaped soil dwelling bacterium. The bacterium can infect both animals and humans through direct contact via inhalation, ingestion, or open wounds. Signs and symptoms include fever, cough, chest pain, headache and anorexia. Risk factors include liver disease, diabetes, and thalassemia.
The Burkholderia Pseudomallei Infections (Melioidosis) pipeline drugs market research report provides a comprehensive information on the therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burkholderia pseudomallei Infections (Melioidosis) and features dormant and discontinued projects.
Melioidosis Pipeline Drugs Market Segmentation by Targets
The key targets in the Melioidosis pipeline drugs market are Beta Lactamase, DNA Gyrase, DNA Topoisomerase IV, Elongation Factor G, Enoyl [Acyl Carrier Protein] Reductase [NADH], Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI, and Leucine tRNA Ligase Cytoplasmics.
Melioidosis Pipeline Drugs Market Analysis, by Targets
For more insights on Melioidosis pipeline drugs targets, download a free report sample
Melioidosis Pipeline Drugs Market Segmentation by Mechanism of Actions
The key mechanism of actions in the Melioidosis pipeline drugs market are Beta Lactamase Inhibitor, DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, Elongation Factor G Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] Inhibitor, and Leucine tRNA Ligase Cytoplasmic Inhibitor.
Melioidosis Pipeline Drugs Market Analysis, by Mechanism of Actions
For more insights on Melioidosis pipeline drugs mechanism of actions, download a free report sample
Melioidosis Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Melioidosis pipeline drugs market are intravenous, oral, and muscular.
Melioidosis Pipeline Drugs Market Analysis, by Routes of Administration
For more insights on Melioidosis pipeline drugs routes of administration, download a free report sample
Melioidosis Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the Melioidosis pipeline drugs market are small molecule, conjugate vaccine, synthetic peptide, and vaccine.
Melioidosis Pipeline Drugs Market Analysis, by Molecule Types
For more insights on Melioidosis pipeline drugs molecule type, download a free report sample
Competitive Landscape
Some of the leading companies in the Melioidosis pipeline drugs market are Aceragen Inc, AN2 Therapeutics Inc, Bugworks Research Inc, Entasis Therapeutics Holdings Inc, and Soligenix Inc.
Melioidosis Pipeline Drugs Market Overview
Key Targets | Beta Lactamase, DNA Gyrase, DNA Topoisomerase IV, Elongation Factor G, Enoyl [Acyl Carrier Protein] Reductase [NADH], Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI, and Leucine tRNA Ligase Cytoplasmics |
Key Mechanism of Actions | Beta Lactamase Inhibitor, DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, Elongation Factor G Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] Inhibitor, and Leucine tRNA Ligase Cytoplasmic Inhibitor |
Key Routes of Administration | Intravenous, Oral, and Muscular |
Key Molecule Types | Small Molecule, Conjugate Vaccine, Synthetic Peptide, and Vaccine |
Leading Companies | Aceragen Inc, AN2 Therapeutics Inc, Bugworks Research Inc, Entasis Therapeutics Holdings Inc, and Soligenix Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
AN2 Therapeutics Inc
Bugworks Research Inc
Entasis Therapeutics Holdings Inc
Soligenix Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Melioidosis pipeline drugs market?
The key targets in the Melioidosis pipeline drugs market are Beta Lactamase, DNA Gyrase, DNA Topoisomerase IV, Elongation Factor G, Enoyl [Acyl Carrier Protein] Reductase [NADH], Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI, and Leucine tRNA Ligase Cytoplasmics.
-
What are the key mechanism of actions in the Melioidosis pipeline drugs market?
The key mechanism of actions in the Melioidosis pipeline drugs market are Beta Lactamase Inhibitor, DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, Elongation Factor G Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] Inhibitor, and Leucine tRNA Ligase Cytoplasmic Inhibitor.
-
What are the key routes of administration in the Melioidosis pipeline drugs market?
The key routes of administration in the Melioidosis pipeline drugs market are intravenous, oral, and muscular.
-
What are the key molecule types in the Melioidosis pipeline drugs market?
The key molecule types in the Melioidosis pipeline drugs market are small molecule, conjugate vaccine, synthetic peptide, and vaccine.
-
Which are the leading companies in the Melioidosis pipeline drugs market?
The leading companies in the Melioidosis pipeline drugs market are Aceragen Inc, AN2 Therapeutics Inc, Bugworks Research Inc, Entasis Therapeutics Holdings Inc, and Soligenix Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.